bullish
Jiangsu Hengrui Pharma A/H Listing - Low-End Is Probably Close to Fair Value
417 Views15 May 2025 12:17
Jiangsu Hengrui Medicine (600276 CH), a China-based pharmaceutical company, aims to raise around US$1.3bn in its H-share listing. In this note, we talk about the deal pricing.
What is covered in the Full Insight:
- Introduction
- Deal Details
- Market Performance
- Valuation and A/H Premium
- Summary and Conclusion
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Jiangsu Hengrui Pharma A/H Trading - Strong Demand for Quality Asset, but Is Pricey23 May 2025
- Eastroc Beverage A/H Listing - Energized - Fast Growth, Better Margins21 May 2025
- ECM Weekly (19 May 2025) - CATL, Hengrui, Green Tea, SMPP, Unisound, Renesas, Genda, GMO, PayTM19 May 2025
- CATL A/H Listing - High Quality, Large Size Make It Unavoidable but Needs a Discount12 May 2025
- Jiangsu Hengrui Pharma A/H Listing - PHIP Updates and Updated Thoughts on A/H Premium08 May 2025
- Jiangsu Hengrui Pharma A/H Listing - Recent Updates and Thoughts on A/H Premium10 Apr 2025
x